Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (141)	1/16/1999 3:59:00 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 613

Just finished new edition of Barron's and came across ATRX and the fact that insiders bought over 36,000 shares lately. Here is a biotech with approved product and therefore has source of revenue and the stock is down nearly 50% from it recent high. Do you know anything about them. Surprised there is no thread here on SI. I might start one after more DD.

To: Mike McFarland who wrote (141)	1/17/1999 12:30:00 AM
From: RCMac	Respond to of 613

>>BTRN has been added to VD's model portfolio, I don't remember seeing any reason for the trade, but maybe MEDI hinted at favorable data at H&Q?<< More than hinted, according to Rick Harmon: >>MEDI presentation yesterday....... "first and foremost, about MEDI-507, our anti-T cell monoclonal antibody for immunosuppression, we've been studying that in a number of clinical trials. We've just finished a phase II trial in graft-versus host disease with very positive results and expect to be presenting data on that later this year....."<< Message 7274274 MEDI-507 is the monoclonal antibody, formerly known as BTI-322, that BTRN and MEDI are collaborating on. This is BTRN's most advanced program, and is described at length at pages 2-3 of its 1997 annual report, and in other items in the BTRN investor's package. Results of an earlier small (20-patient) Phase II trial of BTI-322/MEDI-507were reported in July at the 17th Annual World Congress Meeting of the Transplantation Society, showing favorable results in suppressing GvHD: fkpi.com What Rick quotes from BTRN at H&Q suggests that development of this very promising mAb is proceeding apace, and is likely the reason Rman and V1 have added BTRN to the VDXX portfolio. I assume that if the data will be presented "later this year", BTRN is not due for an immediate pop, but bear in mind that the stock is trading for about the value of its cash in the bank, so IMO the risk-reward ratio looks very attractive. -- RCM